Show simple item record

dc.contributor.authorHazboun, Nader
dc.date.accessioned2018-11-28T09:41:21Z
dc.date.available2018-11-28T09:41:21Z
dc.date.issued2017-04
dc.identifier.issn10.5923/j.ijtt.20170601.01
dc.identifier.issn10.5923/j.ijtt.20170601.02
dc.identifier.urihttp://dspace.bethlehem.edu:8080/xmlui/handle/123456789/85
dc.description.abstractCancer treatment for hematological malignancies traditionally included systemic chemotherapy and localized radiotherapy for central nervous system (CNS) disease. These therapies in addition to their adverse effects’ profile do not induce complete responses in all patients. The development of chimeric antigen receptor (CAR) technology enables the targeting of tumors with high affinity and specificity leading to unprecedented responses among refractory/relapsed patients with various blood malignancies. This mini-review summarizes the role of CAR-T cells for the treatment of blood cancer highlighting potential areas of improvements.en_US
dc.language.isoenen_US
dc.publisherScientific & Academic Publishingen_US
dc.subjectImmunotherapy, Monoclonal antibody, Chimeric antigen receptor T-cellsen_US
dc.titleCancer Immunotherapy with CAR-T cells for Hematological Malignanciesen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record